172 related articles for article (PubMed ID: 32674208)
1. Phase 3 HERO Trial Finds Relugolix to Be Superior to Leuprolide in Prostate Cancer.
Slater H
Oncology (Williston Park); 2020 Jul; 34(7):252. PubMed ID: 32674208
[TBL] [Abstract][Full Text] [Related]
2. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
[TBL] [Abstract][Full Text] [Related]
3. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
4. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
Shore ND; Sutton J
Future Oncol; 2022 Jul; 18(21):2575-2584. PubMed ID: 35587650
[TBL] [Abstract][Full Text] [Related]
5. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N
Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
Spratt DE; George DJ; Shore ND; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown BA; Lu S; Fallick M; Hanson S; Tombal BF
JAMA Oncol; 2024 May; 10(5):594-602. PubMed ID: 38451492
[TBL] [Abstract][Full Text] [Related]
7. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Shore ND; Mehlhaff BA; Cookson MS; Saltzstein DR; Tutrone R; Brown B; Lu S; Fallick M; Hanson S; Saad F
Adv Ther; 2023 Nov; 40(11):4919-4927. PubMed ID: 37713020
[TBL] [Abstract][Full Text] [Related]
8. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
9. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
10. Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
Rush HL; Gilbert DC; Langley RE
Eur Urol; 2024 Jun; 85(6):e164-e165. PubMed ID: 38584074
[No Abstract] [Full Text] [Related]
11. Relugolix in the management of prostate cancer.
Sahu KK; Tripathi N; Agarwal N; Swami U
Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
[TBL] [Abstract][Full Text] [Related]
12. Relugolix: First Global Approval.
Markham A
Drugs; 2019 Apr; 79(6):675-679. PubMed ID: 30937733
[TBL] [Abstract][Full Text] [Related]
13. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tutrone R; Saad F; George DJ; Tombal B; Bailen JL; Cookson MS; Saltzstein DR; Hanson S; Brown B; Lu S; Fallick M; Shore ND
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38143206
[TBL] [Abstract][Full Text] [Related]
14. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
[TBL] [Abstract][Full Text] [Related]
15. Degarelix.
Frampton JE; Lyseng-Williamson KA
Drugs; 2009 Oct; 69(14):1967-76. PubMed ID: 19747011
[TBL] [Abstract][Full Text] [Related]
16. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
17. Re: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
Pickles T
J Urol; 2005 Dec; 174(6):2423-4; author reply 2424. PubMed ID: 16280866
[No Abstract] [Full Text] [Related]
18. First Oral Hormone for Treating Prostate Cancer.
Aschenbrenner DS
Am J Nurs; 2021 Apr; 121(4):22-23. PubMed ID: 33755620
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
[TBL] [Abstract][Full Text] [Related]
20. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
